SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
As per letter attached06-01-2022
06-01-2022
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Closure of Trading Window
As per letter attached29-12-2021
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Investor Presentation
As per letter attached28-12-2021
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Investor Presentation
Transcript of the Investor Presentation made on Thursday, December 09, 202116-12-2021
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
Corrigendum to the Press Release titled - 'SPARC to present updated clinical data of vodobatinib (SCO-088) at the 63rd ASH annual meeting'10-12-2021
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release: SPARC to present updated clinical data of vodobatinib (SCO-088) at the 63rd ASH annual meeting10-12-2021
Business Update: Sun Pharma Advanced Research Company (SPARC)
Conference Call with Sun Pharma Advanced Research Company Ltd. Management and Analysts. Listen to the full earnings transcript.10-12-2021
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation: Update on SPARC strategy and portfolio09-12-2021
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - 532872 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation: Update on SPARC strategy and portfolio09-12-2021
SPARC inks licensing pact with Visiox Pharma for ophthalmic products
The company has entered into an agreement with Visiox Pharma LLC (Visiox) to grant exclusive worldwide rights (except for India and Greater China) for the development and commercialisation of PDP-716 and SDN-037, SPARC said in a statement.08-12-2021